Sarcopenia assessment by new EWGSOP2 criteria for predicting chemotherapy dose-limiting toxicity in patients with gastrointestinal tract tumors

Basit Öğe Kaydı
dc.authoridCelik, Emir/0000-0001-8440-3082
dc.authoridASLAN, Muhammed Samil/0000-0002-6419-951X
dc.contributor.authorCelik, Emir
dc.contributor.authorSuzan, Veysel
dc.contributor.authorSamanci, Nilay Sengul
dc.contributor.authorSuzan, Aysegul Akkan
dc.contributor.authorKaradag, Mehmet
dc.contributor.authorSahin, Serdar
dc.contributor.authorAslan, Muhammed Samil
dc.date.accessioned2024-09-18T20:56:50Z
dc.date.available2024-09-18T20:56:50Z
dc.date.issued2022
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractIntroduction In 2019, The EWGSOP2 group made updates on the definition and diagnosis of sarcopenia. The aim of this study is to determine the possible risk factors for chemotherapy dose-limiting toxicity (DLT). Methods Newly diagnosed gastrointestinal (GI) cancer patients were included in this prospective observational study. Chemotherapy DLTs were recorded in patients receiving platinum-based therapy. The patients were divided into two groups according to the current sarcopenia criteria. Results 75 patients were included in the final analysis. Chemotherapy DLT occurred in 52% (n = 39) of all patients who received platinum-based chemotherapy. DLT rates were 78.9% and 42.9% in sarcopenic and non-sarcopenic patients, respectively (p = 0.007). According to the results of the multivariate analysis, the only sarcopenia was found as a statistically significant risk factor for DLT. Conclusion Assessment of sarcopenia evaluated with the current EWGSOP2 diagnostic criteria is useful in predicting chemotherapy DLT development in patients with a diagnosis of GI cancer. In the future, current EWGSOP2 recommendations should be considered while designing a study investigating the correlation between sarcopenia and chemotoxicity. Key summary pointsAim To determine the possible risk factors for chemotherapy dose-limiting toxicity (DLT) in patients with gastrointestinal (GI) cancer. Findings The only sarcopenia was found as a statistically significant risk factor for chemotherapy DLT. Message Assessment of sarcopenia evaluated with the current EWGSOP2 diagnostic criteria is useful in predicting chemotherapy DLT development in GI cancer patients.en_US
dc.identifier.doi10.1007/s41999-021-00592-3
dc.identifier.endpage274en_US
dc.identifier.issn1878-7649
dc.identifier.issn1878-7657
dc.identifier.issue1en_US
dc.identifier.pmid34826111en_US
dc.identifier.scopus2-s2.0-85119964195en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage267en_US
dc.identifier.urihttps://doi.org/10.1007/s41999-021-00592-3
dc.identifier.urihttps://hdl.handle.net/20.500.12483/12115
dc.identifier.volume13en_US
dc.identifier.wosWOS:000722807600002en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofEuropean Geriatric Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSarcopeniaen_US
dc.subjectChemotherapy dose-limiting toxicityen_US
dc.subjectEWGSOP2 criteriaen_US
dc.titleSarcopenia assessment by new EWGSOP2 criteria for predicting chemotherapy dose-limiting toxicity in patients with gastrointestinal tract tumorsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu